Results 51 to 60 of about 4,521 (200)

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 274-285, July 2026.
BRAF inhibitors and MEK inhibitors (MEKi) have reshaped the treatment of BRAFV600‐mutant malignancies; however, cutaneous adverse drug reactions (ADRs) remain a frequent and clinically impactful toxicity. Although clinical trials provide insight into their safety profiles, real‐world data on dermatologic ADRs are limited.
Natalia Sauer, Piotr Giedziun, Jacek Calik, Anna Wiela‐Hojeńska   +3 more
wiley   +1 more source

Plexiform neurofibroma in a 16-year-old girl

, 2012
Plexiform neurofibroma is a rare, poorly defined benign tumor of the peripheral nerve sheath. It spreads out just under the skin, or deeper in the body, and occurs exclusively in patients with neurofibromatosis type I.
Yadav, D.S., Bhatia, Deepak, Anand, Reena, Yadav, Deepali, Yadav, Vikram   +4 more
core   +1 more source

Plexiform Neurofibroma of Face: A Challenge for Plastic Surgeons

Journal of the Dow University of Health Sciences, 2009
Plexiform neurofibroma is a benign tumour of peripheral nerves and connective tissue. They developmost often in patients with neurofibromatosis type 1 (NF1) and often grow continuously.
Muhammad Ahmad, Saleem A. Malik
doaj   +4 more sources

Solitary Plexiform Neurofibroma of the Gingiva: Unique Presentation in the Oral Cavity [PDF]

Journal of Clinical and Diagnostic Research, 2013
Neurofibromas are benign tumours originating from the nerve sheath. Amongst the histological variants, plexiform types are considered exclusive. These are poorly circumscribed, locally invasive and may exhibit sarcomatous potential.
SURAMYA S., PRATIBHA SHASHIKUMAR, SHREESHYLA H.S., SHEELA KUMAR G.   +3 more
doaj   +1 more source

Rapid Response to Trametinib Combined With Chemotherapy for Infant BRAF‐Fused Chiasmatic Glioma

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Infants, less than 1 year, with chiasmatic gliomas (ICG) present a major therapeutic challenge due to large tumor size, decreased vision, rapid progression, and poor response to vincristine/carboplatin chemotherapy. The majority have a BRAF fusion, which may respond to downstream MEK inhibitors but response time is slow. There are no safety or
Helen Toledano, Alexander Yelak, Walid Kaadan, Shlomo Caduri, Rivka Friedland, Orli Michaeli, Gad Dotan, Osnat Konen   +7 more
wiley   +1 more source

Neurodevelopmental and Psychiatric Studies in Children and Adolescents With Neurofibromatosis Type I: A Comprehensive Scoping Review

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, Volume 201, Issue 4, Page 257-269, June 2026.
ABSTRACT A comprehensive synthesis of the broad range of neurodevelopmental and psychiatric manifestations in NF1 is needed to identify knowledge gaps and future directions for NF1 research. In the following scoping review, we identify and summarize the scope of research that examines neurodevelopmental and psychiatric manifestations, both as ...
Meera Chopra, Tin‐Suet Joan Lee, Jacob Vorstman, Patricia Parkin, Louise Gallagher, Aneta Krakowski   +5 more
wiley   +1 more source

Mediastinal mass in an tuberculosis-exposed 2-year old child with neurofibromatosis type 1 – TB or not TB?

Respiratory Medicine Case Reports, 2021
A toddler with neurofibromatosis type 1 (NF1) was evaluated for tuberculosis (TB) after exposure. Chest X-ray (CXR) revealed a mediastinal mass indicating lymphadenopathy. However, magnetic resonance imaging showed a large plexiform thoracic neurofibroma.
Renate Krüger, Cornelia Potratz, Pablo Hernáiz-Driever, Birgit Lala, Cornelia Feiterna-Sperling   +4 more
doaj   +1 more source

Distribution of diffuse plexiform neurofibroma on the body surface in patients with neurofibromatosis 1 [PDF]

Neurofibromatosis 1 (NF1) is a genetic disease characterized by cutaneous, neurological and osseous abnormalities. Approximately 20% of patients develop plexiform neurofibroma (PN), resulting in impaired quality of life.
26915, 70335975, 26917, 26916, 26918, Yoshida, Yuichi, Imafuku, Shinichi, Koga, Monji, 70174779, Ehara, Yuko, ヤマモト, オサム, 吉田, 雄一, ヨシダ, ユウイチ, 100000284, 山元, 修, 100000279, エハラ, ユウコ, 4733, Yamamoto, Osamu, 4524   +19 more
core   +1 more source

Bilateral Giant Plexiform Neurofibromas In Neurofibromatosis Type 1

Indian Journal of Dermatology, 2002
A single plexiform neurofibroma or two of any type are considered diagnostic of neurofibromatosis type 1 (NF). Plexiform neurofibromas are congenital and pathognomonic for NF-1.
Thappa D . M, Jeevankumar B, Karthikeyan K   +2 more
doaj  

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source